Trials / Completed
CompletedNCT04186494
Effect of Liraglutide vs CPAP on Cardiometabolic Outcomes in Obstructive Sleep Apnea
The Benefit of a Liraglutide-based Weight Management Alone or in Addition to Standard CPAP Therapy on Metabolic Function in Patients With Obstructive Sleep Apnoea (OSA) - an Explorative, Proof-of-concept Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- St Vincent's University Hospital, Ireland · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
This is an explorative, proof-of-concept study exploring the potential therapeutic role of a Liraglutide-based weight loss regimen versus standard CPAP or the combination of both on metabolic parameters, blood pressure, endothelial function, coronary artery calcification, vascular inflammation and apnea/hypopnea index in non-diabetic patients with moderate to severe obstructive sleep apnea
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml | GLP-1 analogue treatment in combination with advice on diet and physical exercise |
| DEVICE | Continuous positive airway pressure treatment | Gold standard treatment for obstructive sleep apnea |
| COMBINATION_PRODUCT | Liraglutide and CPAP | Combination of both treatments |
Timeline
- Start date
- 2019-12-02
- Primary completion
- 2021-12-31
- Completion
- 2022-07-31
- First posted
- 2019-12-04
- Last updated
- 2023-12-18
Locations
1 site across 1 country: Ireland
Source: ClinicalTrials.gov record NCT04186494. Inclusion in this directory is not an endorsement.